Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
138.00    0.00 (0.00%)
Bid:
138.00
Ask:
144.50
Spread: 6.50 (4.71%)
Market Cap: £108.29m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Positive half year update

6 Jul 2005 07:00

Xaar PLC06 July 2005 FOR IMMEDIATE RELEASE 6 July 2005 Xaar plc POSITIVE HALF YEAR TRADING UPDATE Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, presents an update on performance for the six months ended 30 June2005. Results Xaar is pleased to report that revenues for the six months to 30 June 2005 arein line with expectations at close to £20.0m (2004: £16.9m). Profit before tax for the period (and before foreign exchange movements oninter-company loans) is ahead of expectations at around £4.5m (2004: £2.4m on acomparable basis). These figures are stated under UK GAAP to be consistent withcurrent market forecasts. The results reflect a continuing growth in demand for the group's products andthe benefit of increased volumes on manufacturing overhead recovery. Cash at the end of June was in the region of £17.5m, up from £15.4m at the startof the year. This movement includes an increase in working capital and paymentof the final dividend for 2004 of £0.6m. The outlook for the full year continues to be positive. OmniDot Launch The group's OmniDot printhead platform, its new range of products co-developedwith Agfa (and named 'UPH' in its Agfa format), started commercial production inthe second quarter and was officially launched by Agfa at the FESPA tradeshowheld in May in Munich, Germany. FESPA represents the Screen Printing sector of the industry and digital printingaccounted for more than 50% of the stands at the show, with Xaar wellrepresented by its OEMs. Further details of Agfa's revolutionary new digitalinkjet press, the M-Press, and the Anapurna 100 wide format printer can be foundon the Agfa website, www.agfa.com. Announcement of interim results The interim results will be announced in accordance with Xaar's normal timetablein mid-September. The interim results will be prepared under IFRS in accordance with the EUdirective for quoted companies applicable for reporting periods starting on orafter 1 January 2005. The main differences between the two sets of reportingstandards, as they apply to the group, are likely to be in the capitalisation ofcertain research and development costs, the expensing of share option costs andmovements in the valuation of the group's US dollar hedging transactions. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive Bankside Consultants:Steve Liebmann 020-7367-8883 / 07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.